The FDA has approved a once-daily autoinjector for Zilbrysq (zilucoplan), a complement component 5 (C5) inhibitor made by UCB, for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG). This approval doesn't introduce a new drug — it simply adds a more user-friendly delivery option alongside the already-available prefilled syringe.

The approval was backed by two clinical studies and a human factors validation study. The phase 1 DV0012 trial confirmed bioequivalence between the autoinjector and prefilled syringe, while the phase 3b DV0013 study evaluated real-world self-administration in gMG patients. A separate usability study enrolled 100 participants — patients, caregivers, and HCPs alike.

By the Numbers:

• 99.8% complete dose delivery across 449 autoinjector administrations in the phase 3b study
• 90% of participants successfully completed an injection on their first attempt — no training required
• Only 3 patients (9.7%) reported injection-site pain as an adverse event

Why it matters: For patients managing a chronic, debilitating neuromuscular disease, a more intuitive self-injection device can meaningfully improve adherence and quality of life. Neurologists should note that the boxed warning for meningococcal infections and REMS requirements remain in place. Commercial availability is expected in Q1 2027.